CME credits: 0.25

Valid until: 15-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/

Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.

=

CME credits: 0.50

Valid until: 04-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-diagnostic-precision-ai-driven-approaches-in-digital-pathology-and-her2-expression/29878/

With the availability of HER2-directed therapies, it’s important to accurately identify patients who would benefit from these therapies, particularly in breast cancer, where we now have a spectrum of HER2 positivity. Advances in technology have augmented the role of digital pathology (DP) and artificial intelligence (AI) in oncologic pathology. This activity demonstrates how DP/AI can be used for more accurate biomarker assessment and explores the impact this may have on patient outcomes.

=

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/establishing-best-practices-for-collaborative-care-for-patients-with-ascvd-between-academic-and-rural-providers/29824/

This on-demand knowledge primer explores key challenges and evidence-based strategies for improving atherosclerotic cardiovascular disease (ASCVD) management in rural populations. Led by two expert faculty members, the program provides a comprehensive overview of disparities in ASCVD care, guideline-directed therapies, and practical approaches to overcoming barriers in rural settings. Participants will gain essential knowledge to enhance patient outcomes and optimize cardiovascular care in underserved communities.

=

CME credits: 0.75

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/

The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.

=

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00

Valid until: 02-04-2026

Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.